Durvalumab MedChemExpress (MCE)

Product Name	Durvalumab
Synonyms	MEDI4736;Durvalumab
CAS	1428935-60-7
EINECS
Chemical Formula
Molecular Weight
inchi
Package	1 mg;5 mg;10 mg
Price	Email to quote
Descriptions	Durvalumab Durvalumab MedChemExpress (MCE) HY-P9919 1428935-60-7 MEDI 4736 99.60% Please store the product under the recommended conditions in the Certificate of Analysis. Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively. Durvalumab (0.02-20 μg/mL, 3 days) overcomes the inhibitory effect of PD-L1 on T cell activation[1]. Durvalumab (0.1-5 mg/kg, intraperitoneal injection, twice a week, three weeks) suppresses human tumor growth in mouse models through T cell inhibition[1]. IC50: 0.1 nM (PD-L1/PD-1), 0.04 nM (PD-L1/CD80)[2] In Vitro Durvalumab (0.02-20 μg/mL, 3 days) overcomes the inhibitory effect of PD-L1 on T cell activation[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Durvalumab Related Antibodies Human Human IgG1 kappa Human IgG1 kappa, Isotype Control \| \| \| \| \| \| \| \| \| \| [1]. Stewart R, et al. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody. Cancer Immunol Res. 2015 Sep Descriptions Durvalumab Durvalumab MedChemExpress (MCE) HY-P9919 1428935-60-7 MEDI 4736 99.60% Please store the product under the recommended conditions in the Certificate of Analysis. Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively. Durvalumab (0.02-20 μg/mL, 3 days) overcomes the inhibitory effect of PD-L1 on T cell activation[1]. Durvalumab (0.1-5 mg/kg, intraperitoneal injection, twice a week, three weeks) suppresses human tumor growth in mouse models through T cell inhibition[1]. IC50: 0.1 nM (PD-L1/PD-1), 0.04 nM (PD-L1/CD80)[2] In Vitro Durvalumab (0.02-20 μg/mL, 3 days) overcomes the inhibitory effect of PD-L1 on T cell activation[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Durvalumab Related Antibodies Human Human IgG1 kappa Human IgG1 kappa, Isotype Control \| \| \| \| \| \| \| \| \| \| [1]. Stewart R, et al. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody. Cancer Immunol Res. 2015 Sep 3(9):1052-62. [Content Brief] [2]. Faiena I, et al. Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. Drug Des Devel Ther. 2018 Jan 23 12:209-215. [Content Brief]
Last Update	2025-04-01 14:45:47

MedChemExpress (MCE) also provides

Depatuxizumab

Category: Inhibitory Antibodies
CAS: 1471999-69-5
Last Update: 2025-04-01 14:45:47

Raxibacumab

Category: Inhibitory Antibodies
CAS: 565451-13-0
Last Update: 2025-04-01 14:45:47

Crizanlizumab

Category: Inhibitory Antibodies
CAS: 1690318-25-2
Last Update: 2025-04-01 14:45:47

Sofituzumab vedotin

Category: Inhibitory Antibodies
CAS: 1418200-58-4
Last Update: 2025-04-01 14:45:47

Fazpilodemab

Category: Inhibitory Antibodies
CAS: 2517935-02-1
Last Update: 2025-04-01 14:45:47

Osemitamab

Category: Inhibitory Antibodies
CAS: 2460539-61-9
Last Update: 2025-04-01 14:45:47

Visugromab

Category: Inhibitory Antibodies
CAS: 2556646-63-8
Last Update: 2025-04-01 14:45:47

Vobramitamab

Category: Inhibitory Antibodies
CAS: 2490556-50-6
Last Update: 2025-04-01 14:45:47


Supplier Name	MedChemExpress (MCE)
Contact	sales
Tel	609-228-6898
Mobile	609-228-6898
QQ
Email	sales@medchemexpress.com; tech@medchemexpress.com
Website	https://www.medchemexpress.com/
Wechat

Request for quotation

Supplier Contact